Bacillus Clausii in Liver Transplantation

Status Active, not recruiting

Clinical Trial Summary

A prospective, randomized, controlled study of the safety and efficacy of using Bacillus clausii probiotic oral preparation to decrease the incidence of infection during the first 30 days after living donor liver transplantation surgery.

Clinical Trial Description

Patients planned for living donor liver transplantation would be randomized to either intervention or control group 2 weeks before surgery. Intervention group shall receive Bacillus clausii probiotics for 2 weeks. patients in both groups would be followed-up for adverse events and signs and symptoms of infection up to 30 days postoperatively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05047406
Study type	Interventional
Source	Ain Shams University
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	September 7, 2021
Completion date	August 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02463214` - Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients	N/A
Recruiting	`NCT05198570` - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Completed	`NCT01808456` - Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.	Phase 4
Suspended	`NCT01301118` - Graft Take and Microbiology in Burns	N/A
Completed	`NCT00610961` - Induction Related BK Viremia in Renal Transplant Patients	Phase 4
Recruiting	`NCT05215327` - High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients	Phase 2
Recruiting	`NCT05193058` - Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
Unknown status	`NCT01983761` - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation	Phase 1/Phase 2
Active, not recruiting	`NCT02811835` - TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN)	N/A
Completed	`NCT01471444` - Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	Phase 3
Enrolling by invitation	`NCT01349738` - Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants	N/A
Terminated	`NCT00473824` - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation	Phase 2
Completed	`NCT01276457` - Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients	Phase 3
Completed	`NCT00177801` - Organ Transplant Infection Prevention and Detection Project	Phase 4
Completed	`NCT02328963` - Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A	Phase 4
Recruiting	`NCT04320303` - CMV Infection and Immune Intervention After Transplantation	N/A
Active, not recruiting	`NCT01295645` - Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis	Phase 2
Completed	`NCT02329808` - Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
Completed	`NCT01471067` - Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies	Phase 1
Recruiting	`NCT04579471` - Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study